Zdrowie i gospodarka · 03/12/2009

FDA Clears Path for ABILIFY DISCMELT Orally Disintegrating Tablets

The FDA has determined that ABILIFY DISCMELT (aripiprazole) orally disintegrating tablets, 20 mg and 30 mg, were not withdrawn from sale due to safety or effectiveness concerns. This decision enables the FDA to potentially approve abbreviated new drug applications (ANDAs) for these tablets, pending compliance with all applicable laws and regulations.